Osteoarthritis, a degenerative joint disease affecting millions, often leaves patients with persistent pain and stiffness that worsens over time. Current treatments, such as over-the-counter pain relievers or steroid injections, mainly address symptoms without halting the underlying damage to cartilage. Now, researchers at Yale University have developed a potential two-in-one solution: an injectable hydrogel that delivers the drug lacosamide directly into the joint, showing in preclinical tests that it can both ease pain and help rebuild cartilage.

Key takeaways

  • Lacosamide, a drug already approved for nerve pain, was delivered via a hydrogel directly into osteoarthritic joints in animal models.
  • The treatment reduced pain and reversed cartilage degeneration, with no major side effects observed.
  • Unlike current therapies that only manage symptoms, this approach targets pain and tissue repair at the same time.

How the hydrogel works

The Yale team, led by Dr. Choukri Medlej and colleagues, designed a hydrogel made from a biocompatible polymer that can be injected as a liquid but quickly forms a gel inside the joint. This gel serves as a reservoir, slowly releasing lacosamide over time. Lacosamide is currently used to treat certain types of neuropathic pain and seizures, but the researchers discovered it also has a strong effect on the inflammatory and degenerative processes in osteoarthritis.

In the study, which was published in the journal Bioactive Materials, the hydrogel-lacosamide combination was injected into the knees of rats with induced osteoarthritis. The researchers measured pain sensitivity, joint swelling, and cartilage thickness over several weeks. Animals that received the treatment showed significantly less pain behavior and had thicker, healthier cartilage compared to control groups. The hydrogel alone or lacosamide alone did not produce the same level of benefit.

Dual action: pain relief and regeneration

Osteoarthritis involves a breakdown of the smooth cartilage that cushions joints, leading to bone-on-bone contact, inflammation, and pain. Most existing drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, primarily address inflammation or block pain signals temporarily. They do not stimulate cartilage regrowth.

The Yale study suggests that lacosamide, when delivered locally via the hydrogel, acts on multiple pathways. It reduces the activity of pain-sensing nerve fibers and also influences cellular processes that promote cartilage repair. In the treated animals, the researchers observed increased production of collagen and proteoglycans, the building blocks of cartilage, along with decreased markers of inflammation and joint destruction.

Comparison with current treatments

Standard care for osteoarthritis often begins with lifestyle changes and physical therapy, then progresses to oral pain relievers and topical creams. For more advanced cases, doctors may recommend intra-articular injections of corticosteroids or hyaluronic acid. Corticosteroids can provide quick pain relief but may accelerate cartilage loss if used repeatedly. Hyaluronic acid injections aim to lubricate the joint but have mixed evidence for long-term benefit.

According to the Yale researchers, the lacosamide hydrogel approach differs because it combines pain management with structural repair. They highlight that no currently approved treatment for osteoarthritis has convincingly shown the ability to regenerate lost cartilage. If the results are confirmed in human trials, this could represent a major shift in how the disease is managed.

What the study shows and what it does not

The study, conducted in a rat model of osteoarthritis, provides strong evidence that the hydrogel-based delivery system works and is safe in animals. The researchers saw no signs of toxicity or adverse reactions at the injection site. However, the authors caution that animal results do not always translate directly to humans. The next step will be to test the treatment in human clinical trials, which could take several years.

Another limitation is that the study only lasted a few weeks. Long-term effects, including whether the cartilage repair is durable and whether repeated injections would be needed, remain unknown. The hydrogel formulation also needs to be optimized for human use, including a proper dosing schedule.

Potential implications for millions

Osteoarthritis is the most common form of arthritis, affecting more than 32 million adults in the United States alone. It is a leading cause of disability, especially among older adults. The economic burden, including medical costs and lost wages, is substantial. A treatment that could both control pain and slow or reverse cartilage damage would have a major public health impact.

The Yale team is now working on scaling up production of the hydrogel and planning early-phase human trials. If successful, the treatment could offer a new option for patients who have limited choices today, particularly those who are not candidates for joint replacement surgery.

Frequently asked questions

What is lacosamide and how is it currently used?

Lacosamide is an FDA-approved medication used primarily for the treatment of partial-onset seizures in epilepsy and for diabetic neuropathic pain. It works by slowing down nerve impulses that cause seizures or pain. In the Yale study, researchers discovered it also has properties that help reduce inflammation and stimulate cartilage repair in osteoarthritis.

How is the hydrogel different from existing osteoarthritis injections?

Existing injections for osteoarthritis, like corticosteroids or hyaluronic acid, mainly provide temporary pain relief or lubrication. They do not repair damaged cartilage. The hydrogel developed at Yale serves as a sustained-release system for lacosamide, which not only reduces pain but also promotes cartilage regeneration. The hydrogel itself is biocompatible and breaks down over time, leaving no permanent material in the joint.

When might this treatment be available for humans?

The treatment is still in the preclinical stage. The Yale researchers are planning to move toward human clinical trials, which typically take several years to complete, including phases for safety and efficacy. If results are positive, it may be several more years before regulatory approval and widespread availability. Patients should continue to follow current treatment guidelines and consult their doctors for the best options today.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.